Literature DB >> 7665664

Initial use of a broth microdilution method suitable for in vitro testing of fungal isolates in a clinical microbiology laboratory.

D M Hacek1, G A Noskin, K Trakas, L R Peterson.   

Abstract

Antifungal susceptibility testing methods currently lack a standardized procedure. Many factors, such as inoculum preparation, inoculum density, medium selection, pH, incubation time and temperature, and endpoint determination, affect results. We developed a workable procedure for fungal susceptibility testing, with a microtiter method based upon modifications of the proposed guidelines from the National Committee for Clinical Laboratory Standards, using two different growth media. For this procedure, the microtiter tray is prepared as a panel of 6 drugs (amphotericin B, flucytosine, fluconazole, ketoconazole, miconazole, and itraconazole) alone and in combination with amphotericin B. Eagle's minimal essential medium and RPMI 1640 are the two growth media. Two separate susceptibility trays are inoculated for each sensitivity test, with one tray incubated at 30 degrees C and the other incubated at 35 degrees C. After 48 h of growth, results for both temperatures and both media are recorded and interpreted. The four test environments (two media each at two temperatures) provided growth for 100 of the first 104 organisms that were submitted for testing. This approach provides a workable methodology for routine antifungal susceptibility testing in a clinical microbiology laboratory setting.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7665664      PMCID: PMC228291          DOI: 10.1128/jcm.33.7.1884-1889.1995

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  14 in total

Review 1.  Resistance of Candida species to fluconazole.

Authors:  J H Rex; M G Rinaldi; M A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

Review 2.  Amphotericin B: current understanding of mechanisms of action.

Authors:  J Brajtburg; W G Powderly; G S Kobayashi; G Medoff
Journal:  Antimicrob Agents Chemother       Date:  1990-02       Impact factor: 5.191

Review 3.  Temperature and host defense.

Authors:  N J Roberts
Journal:  Microbiol Rev       Date:  1979-06

4.  A pharmacologic guide to the clinical use of amphotericin B.

Authors:  D D Bindschadler; J E Bennett
Journal:  J Infect Dis       Date:  1969-10       Impact factor: 5.226

Review 5.  Antifungal susceptibility testing.

Authors:  J H Rex; M A Pfaller; M G Rinaldi; A Polak; J N Galgiani
Journal:  Clin Microbiol Rev       Date:  1993-10       Impact factor: 26.132

Review 6.  Susceptibility testing of fungi: current status of the standardization process.

Authors:  J N Galgiani
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

7.  Antibiotic susceptibility testing accuracy. Review of the College of American Pathologists Microbiology Survey, 1972-1983.

Authors:  R N Jones; D C Edson
Journal:  Arch Pathol Lab Med       Date:  1985-07       Impact factor: 5.534

8.  In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp.

Authors:  C E Hughes; C Harris; J A Moody; L R Peterson; D N Gerding
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

9.  Susceptibility testing of Candida species for fluconazole: the role of buffering in the agar dilution assay.

Authors:  E Werner; M Seibold; E Antweiler
Journal:  Mycoses       Date:  1993 Mar-Apr       Impact factor: 4.377

Review 10.  Evolving role of flucytosine in immunocompromised patients: new insights into safety, pharmacokinetics, and antifungal therapy.

Authors:  P Francis; T J Walsh
Journal:  Clin Infect Dis       Date:  1992-12       Impact factor: 9.079

View more
  5 in total

1.  Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center.

Authors:  C R Boschman; U R Bodnar; M A Tornatore; A A Obias; G A Noskin; K Englund; M A Postelnick; T Suriano; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

Review 2.  Azole resistance in Candida.

Authors:  D W Denning; G G Baily; S V Hood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-04       Impact factor: 3.267

3.  Effects of incubation time and buffer concentration on in vitro activities of antifungal agents against Candida albicans.

Authors:  M A Tornatore; G A Noskin; D M Hacek; A A Obias; L R Peterson
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

4.  The trailing end point phenotype in antifungal susceptibility testing is pH dependent.

Authors:  K A Marr; T R Rustad; J H Rex; T C White
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

5.  Detection of fluconazole-resistant isolates of Candida glabrata by using an agar screen assay.

Authors:  Susan M Nelson; Charles P Cartwright
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.